Ucb Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Ucb

Access the complete profile.

Ucb Fast Facts

Revenue	Over $500 million    See Exact Annual Revenue
Employees	Over 1,000Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	3252 Resin, Synthetic Rubber & Artificial Synthetic Fibers & Filaments Manufacturing 325412 Pharmaceutical Preparation Manufacturing
Address	1950 Lake Park Dr Smyrna, GA 30080

Note: Revenues for privately held companies are statistical evaluations.


Ucb's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Ucb's annual revenues are Over $500 million (see exact revenue data)
• What industry is the company in?
  • Ucb is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Ucb Annual Revenue and Growth Rate

Ucb	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	Over $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Ucb's revenues are gauged from an analysis of company filings.

Ucb's Income Statement (based on Industry Averages)

Ucb P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Ucb is developing and marketing. Ucb doesn't have any recent trademark applications, indicating Ucb is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
LORTAB Analgesics; oral analgesics; oral analgesics in solution or liquid form; analgesic preparations; pharmaceutical preparations, namely, an analgesic for human consumption taken orally	07/02/2013
KEMSTRO antispasmodic pharmaceutical preparations	08/12/2011
FLUXID Medicine for the treatment of stomach and duodenal ulcers, heartburn and of other diseases caused by too much stomach acid	08/12/2011

See all trademarks and details in the Full Report.

Market Share of Ucb's Largest Competitors

A competitive analysis shows these companies are in the same general field as Ucb, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Ucb. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
UCB	Smyrna, GA	100
IMMUCOR	Norcross, GA	39
ACELLA PHARMACEUTICALS & AVION PHARMACEUTICALS	Alpharetta, GA	27
ALORA PHARMACEUTICALS	Alpharetta, GA	21
SEBELA PHARMACEUTICALS	Roswell, GA	12
CLEARSIDE BIOMEDICAL	Alpharetta, 2Q	2

Future Competition: Ucb's Fastest Growing Competitors

These companies are in the same general field as Ucb and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)